Publicacións nas que colabora con Oihana Murillo Sauca (22)

2013

  1. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes

    Journal of Immunology, Vol. 190, Núm. 12, pp. 6694-6706

2012

  1. CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells

    FASEB Journal, Vol. 26, Núm. 8, pp. 3380-3392

  2. Liver Gene Transfer of Interkeukin-15 Constructs That Become Part of Circulating High Density Lipoproteins for Immunotherapy

    PLoS ONE, Vol. 7, Núm. 12

2010

  1. Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo

    Gene Therapy

2009

  1. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

    European Journal of Immunology, Vol. 39, Núm. 9, pp. 2424-2436

2008

  1. Estudios de orientación terapéutica sobre la biología de la estimulación de cd137 y la transferencia génica de interleukina-15

    Estudios de orientación terapéutica sobre la biología de la estimulación de cd137 y la transferencia génica de interleukina-15

  2. Interleukin-15 liver gene transfer increases the number and function of IKDCs and NK cells

    Gene Therapy, Vol. 15, Núm. 7, pp. 473-483

  3. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

    Trends in Pharmacological Sciences, Vol. 29, Núm. 8, pp. 383-390

  4. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

    Clinical Cancer Research, Vol. 14, Núm. 21, pp. 6895-6906

2007

  1. Absence of surface expression of CD137 (4-1BB) on Myeloid-derived suppressor cells

    Inmunologia, Vol. 26, Núm. 3, pp. 121-126

  2. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

    Expert Opinion on Biological Therapy, Vol. 7, Núm. 5, pp. 599-615

  3. Immunotherapy and immunoescape in colorectal cancer

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5822-5831

  4. The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFNγ

    International Journal of Cancer, Vol. 121, Núm. 6, pp. 1282-1295

2006

  1. El potencial de la inmunomodulación con anticuerpos monoclonales anti-CD137 (4-1BB) para terapia de enfermedades malignas e infecciones viráles crónicas

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 1, pp. 77-96

  2. Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena

    Clinical Cancer Research

  3. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma

    Cancer Research, Vol. 66, Núm. 4, pp. 2442-2450

  4. Recombinant Adenoviral Vectors Turn on the Type I Interferon System without Inhibition of Transgene Expression and Viral Replication

    Molecular Therapy, Vol. 14, Núm. 1, pp. 129-138

2005

  1. Critical appraisal of the current status of dendritic cell based therapy

    Inmunologia, Vol. 24, Núm. 1, pp. 23-32

  2. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8

    International Journal of Cancer, Vol. 116, Núm. 2, pp. 275-281

  3. Indoleamine 2,3-dioxygenase: From tolerance during pregnancy to cancer

    Inmunologia, Vol. 24, Núm. 4, pp. 20-27